Joris B. W. Elbers

Joris B. W. Elbers

Auto-generated profile, based on publicly available information

Joris B. W. Elbers

Department of Radiotherapy, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ALAnne M. van der Leun
Anne M. van der Leun
JTJoleen J.H. Traets
Joleen J.H. Traets
JVJoris L. Vos
Joris L. Vos
JEJoris B.W. Elbers
Joris B.W. Elbers
SPSanne Patiwael
Sanne Patiwael
CZCharlotte Zuur
Charlotte Zuur
To dissect the effect of neoadjuvant PD-1 and CTLA4 blockade on intratumoral T cells in treatment-naive head and neck squamous cell carcinoma, we analyzed primary tumor immune infiltrates from responding and nonresponding patients. At baseline, a higher ratio between active (4-1BB/OX40+) and inactive regulatory CD4+ T cells was associated with immunotherapy response. Furthermore, upon therapy, this active regulatory T-cell (Treg) population showed a profound decrease in responding patients. In an analogous process, intratumoral dysfunctional CD8+ T cells displayed decreased expression of activity and dysfunction-related genes in responding patients, whereas in clinical nonresponders, natural killer cells showed an increased cytotoxic profile early upon treatment. These data reveal immunologic changes in response to dual PD-1/CTLA4 blockade, including a parallel remodeling of presumed tumor-reactive Treg and CD8+ T-cell compartments in responding patients, and indicate that the presence of activated Tregs at baseline may be associated with response. Significance: In head and neck squamous cell carcinoma, neoadjuvant PD-1/CTLA4 blockade has shown substantial response rates (20%–35%). As recognition of tumor antigens by T cells appears to be a critical driver of therapy response, a better understanding of alterations in T-cell state that are associated with response and resistance is of importance. This article is featured in Selected Articles from This Issue, p. 2109

1 January 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JEJoris B.W. Elbers
Joris B.W. Elbers
AAAbrahim Al-Mamgani
Abrahim Al-Mamgani
MTMargot E.T. Tesseslaar
Margot E.T. Tesseslaar
Michiel Van den BrekelMichiel Van den Brekel
Michiel Van den Brekel
CLCharlotte A.H. Lange
Charlotte A.H. Lange
JBJan Paul de Boer
Jan Paul de Boer

14 December 2018 in Head & Neck
Verified
Journal Article
Open access
PDF file
BCBianca Cioni
Bianca Cioni
Ekaterina S. JordanovaEkaterina S. Jordanova
Ekaterina S. Jordanova
EHErik Hooijberg
Erik Hooijberg
RLRianne van der Linden
Rianne van der Linden
RMRenee X. de Menezes
Renee X. de Menezes
JBJan Paul de Boer
Jan Paul de Boer
Background: Human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV‐positive OPSCC patient.Methods: A comprehensive multivariate analysis with clinical and immune variables (human leukocyte antigen [HLA] I/II, programmed death ligand 1 (PD‐L1), programmed death receptor 1 (PD1), T cells, and macrophages) was performed in 142 OPSCC patients.Results: We found an inverse correlation between the expression of HLA class II molecules on tumor cells and CD68+ CD163+ tumor‐associated macrophages (TAMs). High HLA‐DP/DQ/DR expression and low number of TAMs were associated with longer disease‐specific survival and disease‐free survival (DFS). Furthermore, a new population of CD8+ FoxP3+ T cells was correlated with shorter DFS in multivariate analysis.Conclusions: \We identified new prognostic markers for patients with oropharyngeal cancer, which can be used for selecting patients that can benefit from immunotherapy.

16 September 2024
Verified
Other
Open access
ALAnne M. van der Leun
Anne M. van der Leun
JTJoleen J.H. Traets
Joleen J.H. Traets
JVJoris L. Vos
Joris L. Vos
JEJoris B.W. Elbers
Joris B.W. Elbers
SPSanne Patiwael
Sanne Patiwael
CZCharlotte Zuur
Charlotte Zuur
To dissect the effect of neoadjuvant PD-1 and CTLA4 blockade on intratumoral T cells in treatment-naive head and neck squamous cell carcinoma, we analyzed primary tumor immune infiltrates from responding and non-responding patients. At baseline, a higher ratio between active (4-1BB/OX-40+) and inactive regulatory CD4+ T cells was associated with immunotherapy response. Furthermore, upon therapy, this active Treg population showed a profound decrease in responding patients. In an analogous process, intratumoral dysfunctional CD8+ T cells displayed decreased expression of activity and dysfunction-related genes in responding patients, while in clinical non-responders NK cells showed an increased cytotoxic profile early upon treatment. These data reveal immunological changes in response to dual PD-1/CTLA4 blockade, including a parallel remodeling of presumed tumor-reactive Treg and CD8+ T cell compartments in responding patients, and indicate that the presence of activated Tregs at baseline may be associated with response.

16 September 2024
Verified
Other
Open access
PDF file
ALAnne M. van der Leun
Anne M. van der Leun
JTJoleen J.H. Traets
Joleen J.H. Traets
JVJoris L. Vos
Joris L. Vos
JEJoris B.W. Elbers
Joris B.W. Elbers
SPSanne Patiwael
Sanne Patiwael
CZCharlotte Zuur
Charlotte Zuur
Cell state annotations of CD45+ cells and clonality of T cells isolated from HNSCC biopsies.

16 September 2024
Verified
Other
Open access
ALAnne M. van der Leun
Anne M. van der Leun
JTJoleen J.H. Traets
Joleen J.H. Traets
JVJoris L. Vos
Joris L. Vos
JEJoris B.W. Elbers
Joris B.W. Elbers
SPSanne Patiwael
Sanne Patiwael
CZCharlotte Zuur
Charlotte Zuur
Differentially expressed genes in the NK cell subpopulations of responding patients between post- versus pre-treatment.